Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CGP 30083; Epoxymexrenone; Inspra; SC 66110; Selara

Latest Information Update: 25 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Medical University of Graz; Pfizer; Solvotrin Innovations
  • Class Antihypertensives; Heart failure therapies; Lactones; Pregnenes; Small molecules
  • Mechanism of Action Aldosterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart failure; Hypertension
  • Phase III Chronic heart failure
  • Phase II Left ventricular dysfunction
  • No development reported Postmyocardial infarction; Primary hyperparathyroidism

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Jan 2018 No development reported - Phase-III for Primary hyperparathyroidism in Austria (PO)
  • 01 Nov 2016 Pfizer terminates a phase II/III trial due to futility for Heart failure in Canada (PO) (NCT01708798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top